All In Biotech

Drug Trial Radar · NCT03713632

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 545 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

545

Actual

Start

Feb 25, 2019

Primary completion

Sep 23, 2021

Study completion Jul 19, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • SecukinumabDrug

    Secukinumab 300mg every 2 or every 4 weeks

  • PlaceboDrug

    Placebo 300mg every 2 or every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)Time frame: 16 weeks

Locations

108 sites in 32 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Whittier, California

  • Novartis Investigative Site

    Coral Gables, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Sandy Springs, Georgia

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Bellaire, Texas

  • Novartis Investigative Site

    Pflugerville, Texas

  • Novartis Investigative Site

    Norfolk, Virginia

  • Novartis Investigative Site

    Capital Federal, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Barrie, Ontario, Canada

  • Novartis Investigative Site

    Richmond Hill, Ontario, Canada

  • Novartis Investigative Site

    Drummondville, Quebec, Canada

  • Novartis Investigative Site

    Saint-Jérôme, Quebec, Canada

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site

    Zagreb, HRV, Croatia

  • Novartis Investigative Site

    Jihlava, Czechia

  • Novartis Investigative Site

    Ústí nad Labem, Czech Republic, Czechia

  • Novartis Investigative Site

    Aarhus, Denmark

  • Novartis Investigative Site

    Copenhagen NV, Denmark

  • Novartis Investigative Site

    Antony, France

  • Novartis Investigative Site

    Martigues, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Reims, France

  • Novartis Investigative Site

    Rouen, France

  • Novartis Investigative Site

    Saint-Etienne, France

  • Novartis Investigative Site

    Saint-Mandé, France

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.